ArticleJACC. Case reports2026
Adjunctive Cilostazol Therapy for Sinus Node Dysfunction After Heart Transplantation.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjunctive therapy with cilostazol, a phosphodiesterase-3 inhibitor, for sinus node dysfunction (SND) after heart transplantation (HTx) remains unestablished. CASE SUMMARY: We report the case of a 33-year-old woman who developed an atrioventricular junctional rhythm after HTx. Her SND had persisted for more than 3 weeks post-HTx despite treatment with positive chronotropic agents, including isoproterenol and tulobuterol. After the initiation of off-label cilostazol, her heart rate gradually increased. She was discharged without requiring permanent pacemaker implantation. DISCUSSION: This is the first reported case describing the addition of cilostazol to a nonselective β-agonist and a β TAKE-HOME MESSAGE: Cilostazol may represent an adjunctive option for managing severe SND in heart transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.